Plain-English translation of NCT07419841 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing a new experimental medication called in patients with advanced cancers that have stopped responding to standard treatments. The study will evaluate how safe the medication is, how the body handles it, and whether it shows any signs of helping fight cancer. Researchers will start with lower doses and gradually increase them to find the right dose for future studies.
Many patients with advanced kidney, liver, stomach, and endometrial cancers stop responding to existing treatments, leaving them with few options. This study is designed to explore whether this new medication could become a potential future treatment option for these patients.
You likely qualify if…
You likely don't qualify if…
You would receive the experimental medication as an intravenous infusion (through an IV) once every 2 weeks. The study has two phases: first, researchers will test increasing doses in a smaller group of patients to find a safe dose, and then a larger group will receive that dose. You would have regular clinic visits for blood tests, scans, and health monitoring to track how you're responding and watch for any side effects.
AI-generated summary from trial data · Aug 1, 2026 · Not medical advice
United States